EGFR and non-small cell lung carcinoma: In 2020, another companion diagnostic test, FoundationOne Liquid CDx (FoundationOne), which was also based on the detection of EGFR mutations in plasma ctDNA of NSCLC patients, was approved, but using next‐generation sequencing instead of real‐time PCR.